Fundraising Fox

Normunity

28 employees on LinkedIn · 12 known investors

Find your way into Normunity

360 people in our graph share verified history with the Normunity team — schools, employers, funds. One of them is your warm intro.

Cathy Friedmanunlockedknows Rachel Humphrey · together at Harvard University (overlapped)
×2knows the team · via Xilio Therapeutics
knows the team · via Harvard University
×2knows the team · via AstraZeneca
×2knows the team · via The Johns Hopkins University School of Medicine
×2knows the team · via Bayer Pharmaceuticals

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.

BiotechHealthtech

Founders & leadership

RHRachel Humphrey
Rachel HumphreyinFounding Chief Executive OfficerRachel Humphrey is Founding CEO of Normunity, which develops biologic anti-cancer therapies targeting tumor immune evasion mechanisms. She brings over 25 years of pharmaceutical industry experience, including executive roles at Bristol Myers Squibb and AstraZeneca, Chief Medical Officer positions at multiple biotechnology companies, and board service at both public and private firms.
LC
Lieping ChenScientific Founder
MKMitchell Keegan
Mitchell KeeganinChief Development Officer
WLWilliam LaRochelle
William LaRochelleinChief Scientific Officer
SM
Stacy M. PlumChief Technology Officer

Investors · 12

Sanofi Ventures✓ verifiedCambridge · $5M
Taiho Ventures, LLC✓ verifiedMenlo Park
Pfizer Ventures✓ verified
Samsara BioCapital✓ verifiedPalo Alto
Canaan PartnersStamford · $500K – $20M
Connecticut InnovationsNew Haven · $500K – $2M
Pfizer Venture Investments$5M – $20M
HongShan Capital GroupreportedHong Kong · $100K – $50M
Osage Venture PartnersreportedBala Cynwyd · $500K – $3M
YK Bioventuresreported · 2 sourcesBurlingame

Also in the syndicate · 2

Enavate SciencesleadRegeneron Ventures

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
Immunome10 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Companies competing with Normunity for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Normunity raises $75m to advance solid tumour targeting T-cell engagers - Pharmaceutical Technologypharmaceutical-technology.com · Jan 2025Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapiespulse2.com · Jan 2025Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanismsbusinesswire.com · Jan 2025Normunity Raises $65M in Series A Financingfinsmes.com · Oct 2022About Us - Normunitynormunity.com · Aug 2022

Frequently asked questions

What does Normunity do?
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.
Who founded Normunity?
Normunity was founded by Rachel Humphrey, Lieping Chen.
Who are Normunity's investors?
Normunity's investors include Sanofi Ventures, Taiho Ventures, LLC, Pfizer Ventures, Samsara BioCapital, Canaan Partners, Connecticut Innovations, Pfizer Venture Investments, HongShan Capital Group and 2 more.